Inclusion Criteria:

          1. Patient age is ≥ 18 years

          2. Pathologically (histologically or cytologically) proven diagnosis of prostatic
             adenocarcinoma within 180 days of registration.

          3. Patient's with intermediate to high risk prostate cancer and must be recommended to
             undergo pelvic as well as prostatic irradiation.

          4. History/physical examination (to include at a minimum digital rectal examination of
             the prostate and examination of the skeletal system and abdomen) within 90 days prior
             to registration.

          5. Clinically negative lymph nodes as established by imaging (pelvic ± abdominal CT or
             MR), (but not by nodal sampling, or dissection) within 120 days prior to registration.

             • Patients with lymph nodes equivocal or questionable by imaging are eligible if the
             nodes are ≤ 1.5 cm.

          6. No evidence of bone metastases (M0) on bone scan within 120 days prior to
             registration.

             • Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative
             for metastasis.

          7. Baseline serum PSA value performed within 12 weeks (90 days) prior to registration.

          8. ECOG Performance Status 0-1

          9. Patient must be able to provide study specific informed consent prior to study entry.

        Exclusion Criteria:

          1. Evidence of distant metastases

          2. Regional lymph node involvement

          3. Previous radical surgery (prostatectomy), cryosurgery, or HIFU (High-intensity focused
             ultrasound) for prostate cancer

          4. Previous pelvic irradiation or prostate brachytherapy

          5. Planned prostate brachytherapy boost

          6. Previous or concurrent cytotoxic chemotherapy for prostate cancer

          7. Severe acute or chronic medical or psychiatric condition or laboratory abnormality
             that may increase the risk associated with study participation or study drug
             administration, or may interfere with the interpretation of study results, and in the
             judgment of the investigator would make the subject inappropriate for entry into this
             study.

          8. Patients are excluded if they have a history of autoimmune disease that, in the
             opinion of the treating physician would be a contraindication to pelvic radiation
             (e.g., active systemic lupus, progressive scleroderma)

          9. Patients receiving full-dose anticoagulation or clopidogrel

             • Patients taking 81 mg Aspirin po daily may are still eligible for the study

         10. Patients with a history of prior small bowel ulceration